Challenges of Covid 19 Research
Use of COVID 19 biospecimens in research
Since 2019, COVID 19, caused by a mutated strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been responsible for millions of fatalities and fatalities. As a result, the World Health Organization (WHO) formally designated COVID 19 a public health emergency of worldwide concern on January 30, 2020, based on the scope and gravity of the illness. At the same time, researchers worldwide are analyzing COVID 19 biospecimens obtained from people who may have the disease or who have had it confirmed by a physician to identify definitive treatments and more accurate diagnostic tools for better management of the worldwide pandemic.
COVID 19 samples for research are the wide variety of human samples collected from those who are suspected or tested positive for SARS-CoV-2 infection. It consists of serum, plasma, whole blood, oropharyngeal secretions, and nasopharyngeal secretions that have been screened for SARS-CoV-2 antibodies or antigens. After diagnosis, surplus samples are collected, processed, and stored in state-of-the-art biobanks where they are used as in-vitro human COVID 19 infection models for academic research.
Challenges of COVID-19 research.
To better understand the pathophysiology and biology of the SARS-CoV-2 infection, additional study is required due to the steadily expanding number of COVID 19 cases worldwide. Studies on human biospecimens from COVID 19 patients may aid researchers in better understanding the pathophysiology of the infection.
However, there are numerous risks and challenges involved in the research using COVID 19 biospecimens, which include:
Uncertain sample quality: The certification of the chain of custody, biobanking, and collection of human biospecimens may not always be included with research specimens purchased through brokers or biospecimen companies. Since it is essential for the researchers to check the sample's legitimacy and approval from the IRB procedure, it can create concerns about the quality and authenticity of the study samples, which may directly affect the research result and validity.
Accuracy of sample information: It is crucial to obtain pertinent data, such as clinical assessment details, lab investigation results, and patient demographics, for any research involving human biospecimens to properly characterize and conduct an in-depth examination of research samples. Sometimes the information from the sample source needs to be corrected or verified by a licensed medical professional. Therefore, it doesn't follow the good clinical practices (GCP) regulations and IRB processes.
Explore the Largest Inventory of COVID-19 Research Samples.
Let's cooperate to further COVID-19 research worldwide! A sizable inventory of COVID-19 biospecimens from suspected and clinically confirmed patients is available from Central BioHub exclusively for research and development.
Central BioHub addresses all potential hiccups and risks in COVID patient sample procurement, by providing a wide range of well-annotated, precisely screened, and well-preserved human biospecimens, including serum, plasma, oropharyngeal secretions, and nasopharyngeal secretions (Covid19 swab test samples) from world-class biobanks worldwide.
You can also access human serum and plasma samples taken from covid patients and people who have received COVID 19 vaccines. Hurry up, click here to explore the covid 19 biospecimens for research: https://centralbiohub.de/biospecimens/covid-19
Comments
Post a Comment